Epidemiology and treatment patterns of epithelial ovarian cancer

References

• SEER. Cancer statistics factsheets: ovary cancer. Bethesda, MD: National Cancer Institute. 2016.
   Google Scholar
• American Cancer Society. Cancer facts & figures. Vol. 2015. Atlanta: American Cancer Society; 2015.
   Google Scholar
• Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612–618.
   PubMed Web of Science ®Google Scholar
• Previs RA, Kilgore J, Craven R, et al. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. Int J Gynecological Cancer. 2014;24(4):670–675.
   PubMed Web of Science ®Google Scholar
• Anuradha S, Webb PM, Blomfield P, et al. Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study. Med J Aust. 2014;201(5):283–288.
   PubMed Web of Science ®Google Scholar
• Bjorge T, Lukanova A, Tretli S, et al. Metabolic risk factors and ovarian cancer in the metabolic syndrome and cancer project. Int J Epidemiol. 2011;40(6):1667–1677. Epub 2011/10/11
   PubMed Web of Science ®Google Scholar
• Gram IT, Lukanova A, Brill I, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer. 2012;130(9):2204–2210.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Sundquist J, Brandt A, Incidence and mortality in epithelial ovarian cancer by family history of any cancer. Cancer. 2011;117(17):3972–3980. Epub 2011/03/03.
   PubMed Web of Science ®Google Scholar
• Lahmann PH, Cust AE, Friedenreich CM, et al. Anthropometric measures and epithelial ovarian cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer. 2010;126(10):2404–2415.
   PubMed Web of Science ®Google Scholar
• Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol. 2012;175(12):1234–1242. Epub 2012/04/21
   PubMed Web of Science ®Google Scholar
• Ovarian cancer overview. Copyright American cancer society. 2014. [updated 2016 February 03; cited 2016 October 24]. Available from: https://old.cancer.org/acs/groups/cid/documents/webcontent/003070-pdf.pdf.
   Google Scholar
• Aoki D. Annual report of gynecologic oncology committee, Japan society of obstetrics and gynecology, 2013. J Obstetrics Gynaecol Res. 2014;40(2):338–348.
   PubMed Web of Science ®Google Scholar
• Abdullah LS, Bondagji NS, Histopathological pattern of ovarian neoplasms and their age distribution in the western region of Saudi Arabia. Saudi Med J. 2012;33(1):61–65. Epub 2012/01/26.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24–32.
   PubMed Web of Science ®Google Scholar
• Ovarian cancer: recognition and initial management (Clinical Guideline). National Institute for Health and Care Excellence (NICE); 2011. [updated 2011 April 27; cited 2016 October 24]. Available from: https://www.nice.org.uk/guidance/cg122/resources/ovarian-cancer-recognition-and-initial-management-35109446543557.
   Google Scholar
• Cancer NCC-C. Ovarian cancer: the recognition and initial management of ovarian cancer (Full Guidance). 2011. [updated 2011 April; cited 2016 October 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0041115/pdf/PubMedHealth_PMH0041115.pdf.
   Google Scholar
• Usach I, Blansit K, Chen LM, et al. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2015;212(2):188.e1-188.e6.
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN clinical practice guidelines in oncology, ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 2. 2015. [updated 2015 June 22; cited 2016 October 25]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian.
   Google Scholar
• Poveda A, Salazar R, Del Campo JM, et al. Update in the management of ovarian and cervical carcinoma. Clin Translational Oncol. 2007;9(7):443–451.
   PubMed Web of Science ®Google Scholar
• Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl 1):3–11.
   PubMed Web of Science ®Google Scholar
• O’Malley CD, Shema SJ, Cress RD, et al. The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a centers for disease control and prevention study. J Womens Health. 2012;21(9):887–894.
   Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Cress RD, Chen YS, Morris CR, et al. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126(3):491–497.
   PubMed Web of Science ®Google Scholar
• Fuh KC, Shin JY, Kapp DS, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015;136(3):491–497.
   PubMed Web of Science ®Google Scholar
• Cress R, Morris C, Chen Y, et al. Prognostic factors associated with long-term survival in ovarian cancer. Gynecol Oncol. 2014;133:198–199.
   Google Scholar
• Akhtar-Danesh N, Elit L, Lytwyn A. Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: A population-based study. Gynecol Oncol. 2011;123(2):192–195.
   PubMed Web of Science ®Google Scholar
• Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013. Toronto: Canadian Cancer Society; 2013.
   Google Scholar
• Ferlay JSI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014.
   Google Scholar
• UK CR. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence.
   Google Scholar
• Weiderpass E, Oh JK, Algeri S, et al. Socioeconomic status and epithelial ovarian cancer survival in Sweden. Cancer Causes Control. 2014;25(8):1063–1073.
   PubMed Web of Science ®Google Scholar
• Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in Cote d’Or: prognostic factors and trends in relative survival rates over the last 20 years. BMC Cancer. 2010;10:622.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Cancer survival rates, cancer survival in England, patients diagnosed 2005–2009 and followed up to 2010. Vol. 2011. London: ONS; 2011.
   Google Scholar
• Engholm G, Ferly J, Christensen N, et al. NORDCAN: cancer incidence, 980 mortality, prevalence and survival in the Nordic countries. 2014; Version 6.1 (25.04.2014). Copenhagen: Association of the Nordic Cancer Registries, Danish Cancer Society; 2014.
   Google Scholar
• van Altena AM, Karim-Kos HE, de Vries E, et al. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol. 2012;125(3):649–654. Epub 2012/03/01
   PubMed Web of Science ®Google Scholar
• Jung K, Won Y, Kong H, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2011. Cancer Res Treat. 2014;46(2):109–123.
   PubMedGoogle Scholar
• Ferlay JSI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.
   Google Scholar
• Bray FRJ, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–1145.
   PubMed Web of Science ®Google Scholar
• Yahata T, Banzai C, Tanaka K, Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res. 2012;38(4):645–650. Epub 2012/03/03.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Ajiki W, Marugame T, et al. Research Group of Population-Based Cancer Registries of Japan. Monitoring of Cancer Incidence in Japan - Survival 2003–2005 Report (Center for Cancer Control and Information Services, National Cancer Center, 2013) Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 2011;41:40–51.
   Google Scholar
• Chiang YC, Chen CA, Chiang CJ, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24(4):342–351.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu SZ, Zheng RS, et al. Time trends of ovarian cancer incidence in China. Asian Pac J Cancer Prev. 2014;15(1):191–193.
   PubMedGoogle Scholar
• Wei K, Li Y, Zheng R, et al. Ovary cancer incidence and mortality in China, 2011. Chin J Cancer Res. 2015;27(1):38–43.
   PubMed Web of Science ®Google Scholar
• Wong KH, Mang OW, Au KH, et al. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J. 2012;18(6):466–474. Epub 2012/12/12.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Malhotra KP, Sinha S, et al. Profile of gynecologic malignancies reported at a tertiary care center in India over the past decade: comparative evaluation with international data. Indian J Cancer. 2012;49(3):298–302. Epub 2012/12/15.
   PubMed Web of Science ®Google Scholar
• Alghamdi IG, Hussain II, Alghamdi MS, et al. Incidence rate of ovarian cancer cases in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi cancer registry 2001-2008. Int J Women’s Health. 2014;6(1):639–645.
   PubMedGoogle Scholar
• Arab M, Khayamzadeh M, Tehranian A, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer. 2010;47(3):322–327.
   PubMed Web of Science ®Google Scholar
• Sharifian A, Pourhoseingholi MA, Norouzinia M, et al. Ovarian cancer in Iranian women, a trend analysis of mortality and incidence. Asian Pac J Cancer Prev. 2014;15(24):10787–10790.
   PubMedGoogle Scholar
• Portero DSyRV. Intraperitoneal chemotherapy in advanced epithelial ovarian cancer. Informes, Estudios e Investigacion 2006, Ministerio de Sanidad Y Consumo. 2006.
   Google Scholar
• Martín AG, Redondo A, Jurado M, et al. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol. 2013;15(7):509–525.
   Google Scholar
• Komiyama S, Katabuchi H, Mikami M, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. Int J Clin Oncol. 2016;21(3):435–446.
   PubMed Web of Science ®Google Scholar
• Bristow R, Powell M, Al-Hammadi N, et al. Hugh barber outstanding abstract award disparities in epithelial ovarian cancer according to race and socioeconomic status: adherence to National Comprehensive Cancer Network (NCCN) guidelines and survival outcome, a study of 47, 160 patients from the national cancer data base. Gynecol Oncol. 2012;125:S25–S26.
   Google Scholar
• Bristow RE, Chang J, Ziogas A, et al. Spatial analysis of geographic location and adherence to treatment guidelines for advanced-stage ovarian cancer: impact of race and socioeconomic status. Gynecol Oncol. 2014;133:2.
   Google Scholar
• Basu P, De P, Mandal S, et al. Study of ′patterns of care′ of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 2009;46(1):28–33.
   PubMedGoogle Scholar
• Stewart SL, Lakhani N, Brown PM, et al. Gynecologic cancer prevention and control in the national comprehensive cancer control program: progress, current activities, and future directions. J Womens Health. 2013;22(8):651–657.
   Web of Science ®Google Scholar
• Lin JJ, Egorova N, Franco R, et al. Ovarian cancer treatment and survival trends over past decade. J Gen Intern Med. 2014;29:S161–S162.
   Google Scholar
• Seal BS, Yao J, Kish JK, et al. Evaluation of national treatment trends in ovarian cancer. J Clin Oncol. 2014;32:30.
   Web of Science ®Google Scholar
• Parthan A, Gao SK, Song R, et al. Health care resource utilization (HRU) in advanced ovarian cancer-findings from linked seer-medicare data. Value in Health. 2010;13(3):A31.
   Google Scholar
• Johnson SJ, Sorg RA, Borker RD, et al. Chemotherapy treatment patterns in elderly patients initially diagnosed with advanced ovarian cancer. Clin Ovarian Cancer Other Gynecol Malig. 2012;5(2):67–77.
   Google Scholar
• Joseph N, Clark RM, Dizon DS, et al. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol. 2015;137(3):401–405. Epub 2015/04/04
   PubMed Web of Science ®Google Scholar
• Unni SK, Schauerhamer MB, Deka R, et al. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. J Ovarian Res. 2016;9:18.
   PubMed Web of Science ®Google Scholar
• Health NIo. Clinnicaltrial.gov 2017 [cited 2017 January 25]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England J Med. 2012;366(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–1589.
   PubMed Web of Science ®Google Scholar
• Clovis Oncology I. HIGHLIGHTS OF PRESCRIBING INFORMATION: 1090 RUBRACA™ (rucaparib) tablets. 2016. [updated 2016 December; cited 2016 October 25]. Available from: http://clovisoncology.com/files/rubraca-prescribing-info.pdf.
   Google Scholar
• Institute NC. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. 2017. [updated 2017 January; cited 2017 January 26]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#r3.
   Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England J Med. 2016;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Freyer G, McNeish I, Herzog TJ, et al. Current treatment patterns for recurrent epithelial ovarian cancer in 5 european union (EU5: france, Germany, Italy, Spain, UK) countries. Int J Gynecological Cancer. 2013;23(8):884–885.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Harter P, Hilpert F, et al. Treatment patterns in the advanced ovarian cancer population: data from ago QS-OVAR 2008 prospective cohort. Int J Gynecological Cancer. 2013;23(8):597.
   Web of Science ®Google Scholar
• Houben E, Van Haalen HGM, Sparreboom W, et al. Treatment patterns and outcomes of patients diagnosed with ovarian cancer in the Netherlands: A registry study. Value in Health. 2014;17(7):A655.
   Google Scholar
• Kim K, Hernlund E, Hernadi Z, et al. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. Int J Gynecol Cancer. 2013;23(5):823–832. Epub 2013/05/15
   PubMed Web of Science ®Google Scholar
• Pectasides D, Papaxoinis G, Fountzilas G, et al. Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res. 2009;29(2):745–751. Epub 2009/04/01.
   PubMed Web of Science ®Google Scholar
• McNeish I, Freyer G, Herzog TJ, et al. Understanding factors that drive treatment decisions for recurrent epitheilial ovarian cancer in 5 european union (eu5: france, Germany, Italy, Spain, UK) countries. Int J Gynecological Cancer. 2013;23(8):942–943.
   Web of Science ®Google Scholar
• Pignata S, Ferrandina G, Scarfone G, et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES retrospective study. Oncology. 2006;71(5–6):320–326. Epub 2007/09/20
   PubMed Web of Science ®Google Scholar
• Sant M, Lopez MDC, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2191–2205.
   PubMed Web of Science ®Google Scholar
• Rochon J, Du Bois A. Clinical research in epithelial ovarian cancer and patients’ outcome. Ann Oncol. 2011;22(Suppl 7):vii16–vii19.
   PubMed Web of Science ®Google Scholar
• Lyratzopoulos G, Newsome H, Barbiere J, et al. Trends in the surgical management of epithelial ovarian cancer in East Anglia 1995-2006. Eur J Surg Oncol. 2011;37(5):435–441.
   PubMed Web of Science ®Google Scholar
• Hung J, Fereday S, Harnett P, et al., ; . Primary treatment patterns in women recruited to the Australian ovarian cancer study. Hered Cancer Clin Pract. 2012;10(Suppl2):A80.
   Google Scholar
• Jordan S, Steer C, DeFazio A, et al. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer–a population-based study. Gynecol Oncol. 2013;129(2):310–317. Epub 2013/02/14
   PubMed Web of Science ®Google Scholar
• Anuradha S, Donovan PJ, Webb PM, et al. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer–a population-based study. Acta Oncologica. 2016;55(2):226–233.
   PubMed Web of Science ®Google Scholar
• Akhtar-Danesh N, Lytwyn A, Elit L. Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecol Oncol. 2012;127(3):620–624.
   PubMed Web of Science ®Google Scholar
• Guppy AE, Nathan PD, Rustin GJS. Epithelial ovarian cancer: A review of current management. Clin Oncol. 2005;17(6):399–411.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening UKCTOCS): a randomised controlled trial. Lancet; 2015; 387(10022):945-956.
   Google Scholar
• Grady D. Early detection of ovarian cancer may become possible. 1160 The New York Times; 2015. [updated 2015 December 17; cited 2016 October 25]. Available from: https://www.nytimes.com/2015/12/18/health/early-detection-of-ovarian-cancer-may-become-possible.html?_r=0.
   Google Scholar
• Griffiths SE, Lopes T, Edmondson RJ. The role of prophylactic salpingo‐oophorectomy in women who carry mutations of the BRCA genes. Obstet Gynecol. 2005;7(1):23–27.
   Google Scholar
• Ludwig KK, Neuner J, Butler A, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660–669.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. The FDA recommends against using screening tests for ovarian cancer screening: FDA safety communication 2016 [updated 2016 Sep 7;cited 2016 October 25]. Available from: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm519413.htm.
   Google Scholar
• Center MSKC. Screening guidelines 2016 [2016 October 25]. Available from: https://www.mskcc.org/cancer-care/types/ovarian/screening-guidelines-ovarian.
   Google Scholar
• Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening–current status, future directions. Gynecol Oncol. 2014;132(2):490–495.
   PubMed Web of Science ®Google Scholar
• Institute NC. All that glitters: a glimpse into the future of cancer screening 2012 [updated 2012 Nov 27; cited 2016 October 24]. Available from: https://www.cancer.gov/about-cancer/screening/research/future-of-cancer-screening.
   Google Scholar
• Disis M, Patel M, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity. J Clin Oncol. 2016;34(15 Suppl):5533.
   Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–4022.
   PubMed Web of Science ®Google Scholar
• Varga A, Piha-Paul S, Ott P, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol. 2015;33(15_suppl):5510.
   Web of Science ®Google Scholar
• Society AC. Cancer immunotherapy 2015 [updated 2015; cited August 8, 2016]. Available from: https://old.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
   Google Scholar